VA
Vaishali Pharma Ltd (VAISHALI)
₹6.84
Mkt cap
₹97 Cr
P/E ratio
18.90
P/B
1.13
Div yield
0.00%
ROE
6.02%
ROCE
8.93%
EPS (TTM)
₹0.36
Book value
₹6
52W range
5–10
Sector
Healthcare
Price history
Previous close
Incorporated in 1989, Vaishali Pharma Ltd does marketing of pharmaceutical products including active pharmaceutical ingredients [1]
NSE VAISHALI
Health check
Cautious
ValuationCheap
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−30.70% from high₹7
₹5+44.00% from low₹10
Current
₹6.84
Prev close
₹7.23
Day
−5.39%
Price performance
1D
−5.39%
1W
−3.25%
1M
−5.39%
3M
−13.96%
6M
−2.15%
1Y
−28.97%
YTD
−21.74%
Financials
Revenue, profit & margin
P/E ratio
18.9×
VAISHALI is 43% below the sector median of 33.4×
VAISHALI18.9×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.57 | 27.90 | 32.40 | 18.08 | 20.79 | 27.91 | 32.25 | 23.75 | 33.45 | 24.65 | 26.93 | 22.89 | 30.17 | |
| YoY Sales growth | -4.48% | +38.88% | +23.48% | +34.72% | +65.39% | +0.04% | -0.46% | +31.36% | +60.89% | -11.68% | -16.50% | -3.62% | -9.81% | |
| Expenses | 9.92 | 24.95 | 39.19 | 15.73 | 18.37 | 26.55 | 38.29 | 22.38 | 32.06 | 23.09 | 27.13 | 21.40 | 28.11 | |
| Operating Profit | 2.65 | 2.95 | -6.79 | 2.35 | 2.42 | 1.36 | -6.04 | 1.37 | 1.39 | 1.56 | -0.20 | 1.49 | 2.06 | |
| OPM % | 21.08% | 10.57% | -20.96% | 13.00% | 11.64% | 4.87% | -18.73% | 5.77% | 4.16% | 6.33% | -0.74% | 6.51% | 6.83% | |
| Other Income | 0.30 | 0.47 | 0.91 | 0.42 | 0.71 | 1.07 | 1.00 | 0.84 | 0.84 | 0.89 | 1.26 | 0.58 | 0.95 | |
| Interest | 0.47 | 0.43 | 0.40 | 0.38 | 0.38 | 0.38 | 0.44 | 0.33 | 0.40 | 0.51 | 0.72 | 0.20 | 0.39 | |
| Depreciation | 0.12 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.17 | 0.13 | 0.16 | 0.14 | 0.14 | |
| Profit before tax | 2.36 | 2.87 | -6.42 | 2.27 | 2.63 | 1.93 | -5.60 | 1.74 | 1.66 | 1.81 | 0.18 | 1.73 | 2.48 | |
| Tax % | 27.97% | 26.13% | -26.95% | 25.11% | 25.10% | 24.87% | -23.39% | 26.44% | 28.31% | 28.18% | -50.00% | 13.87% | 16.94% | |
| Net Profit | 1.70 | 2.11 | -4.68 | 1.70 | 1.97 | 1.44 | -4.29 | 1.28 | 1.18 | 1.30 | 0.27 | 1.49 | 2.07 | |
| EPS in Rs | 0.16 | 0.20 | -0.44 | 0.16 | 0.18 | 0.13 | -0.40 | 0.12 | 0.09 | 0.10 | 0.02 | 0.11 | 0.15 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.00% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | −2.00% |
| +1 day | −1.18% |
| +5 days | −4.58% |
| +15 days | −1.65% |
| +30 days | −1.41% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202631.61%Promoter
Promoters31.61%
Public68.39%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Vaishali Pharma | ₹7.17 | 18.87 | 97 | 0.00% | 2 | +75.42% | 30 | −9.81% | 8.93% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports7
Concall transcripts6
Announcements5
Copy of Newspaper Publication 16 Nov - Board approved unaudited Q2 FY2026 results on 14 Nov 2026; newspaper advertisement published.Statement of deviation(s) or variation(s) under Reg. 32 14 Nov - Vaishali Pharma reports no deviation in Rs. 9.08 crore preferential issue proceeds for quarter ended 30 September 2026.Outcome of Board Meeting 14 Nov - Board approved unaudited Q2 and H1 FY2026 financial results on 14 November 2026.Board Meeting - Intimation 7 Nov - Vaishali Pharma Limited has informed about Board Meeting to be held on 14-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company …Board Meeting - Financial Results/Other business matters 7 Nov - Board meets 14 Nov 2026 to approve Q2 and H1 FY2026 unaudited financial results.






